Antiphospholipid Syndrome Diagnosis and Management

Antiphospholipid syndrome is an acquired autoimmune disorder characterised by recurrent arterial or venous thrombosis and pregnancy morbidity in the presence of persistent antiphospholipid antibodies. Diagnostic evaluation combines clinical criteria—such as documented thromboembolic events or adverse obstetric outcomes—with laboratory assays that detect lupus anticoagulant, anticardiolipin antibodies and anti-β2-glycoprotein I antibodies on two or more occasions spaced at least twelve weeks apart. Risk stratification incorporates antibody profile intensity and ‘triple-positive’ status, which confer higher rates of recurrence. Standard management centres on long-term anticoagulation, traditionally with vitamin K antagonists to maintain an international normalised ratio of 2.0–3.0. In patients with obstetric complications, low-dose aspirin and heparin are employed to improve live-birth rates. Emerging strategies include direct oral anticoagulants for selected thrombotic phenotypes, adjunctive therapies such as hydroxychloroquine or statins to modulate inflammation, and targeted interventions against complement activation or neutrophil extracellular trap formation. Individualised care also addresses cardiovascular risk factors, provides multidisciplinary surveillance and seeks novel biomarkers to refine prognostic assessment.

Research from Nature Portfolio

Recent studies have demonstrated that selective agonism of the adenosine A2A receptor can suppress antibody-mediated neutrophil extracellular trap formation and attenuate thrombosis in animal models of the syndrome. By potentiating cyclic AMP signalling, both specific receptor agonists and the antithrombotic agent dipyridamole reduced vascular occlusion in mice challenged with pathogenic antibodies. These findings support an anti-inflammatory therapeutic paradigm that targets innate immune pathways downstream of antiphospholipid antibody binding, offering a potential adjunct to anticoagulant regimens.

Antiphospholipid Syndrome Diagnosis and Management publication trend

The graph below shows the total number of articles in antiphospholipid syndrome diagnosis and management across all publications each year (not limited to Nature Index journals).

Technical terms

Antiphospholipid antibodies (aPL): Autoantibodies directed against phospholipid-binding proteins that promote thrombosis and pregnancy loss.

β2-Glycoprotein I (β2GPI): The principal antigen recognised by pathogenic antiphospholipid antibodies.

Lupus anticoagulant (LA): A functional coagulation assay detecting antibodies that prolong phospholipid-dependent clotting times.

Neutrophil extracellular traps (NETs): Web-like chromatin structures extruded by activated neutrophils that contribute to thrombus formation.

Trimethylation of histone H3 lysine 4 (H3K4me3): An epigenetic mark associated with gene activation implicated in monocyte hyperresponsiveness.

Triple-positive: The concurrent presence of LA, anticardiolipin and anti-β2GPI antibodies, indicating higher clinical risk.

References

1. Diagnosis of antiphospholipid syndrome in routine clinical practice. Lupus (2012).
2. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus (2020).
3. Adenosine receptor agonism protects against NETosis and thrombosis in antiphospholipid syndrome. Nature Communications (2019).
4. H3K4me3‐Mediated FOXJ2/SLAMF8 Axis Aggravates Thrombosis and Inflammation in β2GPI/Anti‐β2GPI‐Treated Monocytes. Advanced Science (2024).
5. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. The Lancet Haematology (2016).